Stopping a clinical trial early: Frequentist and bayesian approaches applied to a CALGB trial in non‐small‐cell lung cancer

Statistics in Medicine

Volumn 13, Issue 13-14, 1994, Pages 1313-1327

  George, Stephen L ^a   Li, Chengchang ^b   Berry, Donald A ^b   Green, Mark R ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BAYES THEOREM; CANCER MORTALITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; FREQUENCY ANALYSIS; HEALTH CARE POLICY; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0028123025     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4780131305     Document Type: Article

References (8)

1. A randomized trial of induction chemotherapy plus high‐dose radiation alone in stage III non‐small cell lung cancer
2. When is a cancer treatment worthwhile?’ (editorial)
3. Chemotherapy and radiation therapy as compared with radiation therapy in stage III non‐small cell cancer’ (letter)
4. Reply to Souhami, et al.’ (letter)
5. Group sequential methods in multi‐institutional cancer clinical trials. A case study
6. Interim analysis in clinical research
7. A case for Bayesianism in clinical trials (with discussion)
8. The relevance of stopping rules in statistical inference (with discussion)